1065O - Comorbidity index in elderly myeloma patients: does it affect clinical outcomes?

Date 01 October 2012
Event ESMO Congress 2012
Session Hematological malignancies
Topics Plasma Cell Dyscrasias
Geriatric Oncology
Presenter Sungmin Kim
Authors S. Kim
  • Medicine, Samsung Medical Center, 135-710 - Seoul/KR



Multiple myeloma occurs mainly in elderly patients older than 60-70 years. Considering high prevalence of comorbid conditions in these age groups, comorbidity may be an important issue in the management of myeloma. However, the effect of comorbidity index on clinical outcome of elderly myeloma patients is not clear, and there is few data analyzing the association between comorbidity and prognosis of myeloma.


We retrospectively analyzed patient aged ≥ 65 years with symptomatic myeloma. All patients were newly diagnosed and not eligible for undergoing autologous stem transplantation. Comorbidity was assessed at the time of diagnosis according to the Charlson Comorbidity Index (CCI).


132 patients were analyzed in this study, and their median age was 71 years (range: 65-92 years) and median follow-up duration was 20 months. Approximately a half of patients (48.5%) had disorders other than myeloma at diagnosis. Diabetes mellitus was the most frequent comorbid disorder (n = 22, 16.7%). The range of CCI score was from 0 to 6. Thus, we classified three groups according to the value of CCI score (0, 1-2, 3-6). When overall survival was compared, the CCI-based classification failed to show a significant survival difference (p = 0.456) although the median survival of each group was as follows: 42.6, 34.1, and 25.3month, respectively). Its relationship with age and performance state was not significant, either (p = 0.151, 0.537). In accordance with this, the frequency of treatment-related complication was also similar among them (p = 0.737).


These results suggest that comorbidity does not affect survival and complications in elderly myeloma patients. Therefore, comorbid disorders may not become a huddle for deciding active treatment in elderly myeloma patients.


All authors have declared no conflicts of interest.